{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:10:37Z","timestamp":1784805037927,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871392"],"award-info":[{"award-number":["81871392"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2021-I2M-1-016"],"award-info":[{"award-number":["2021-I2M-1-016"]}]},{"name":"Capital Health Development Scientific Research Project","award":["2018-1-4011"],"award-info":[{"award-number":["2018-1-4011"]}]},{"name":"Chinese Academy of Medical Science Clinical and Translational Medicine Research Fund","award":["2019XK320032"],"award-info":[{"award-number":["2019XK320032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00259-022-05852-3","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T05:02:36Z","timestamp":1654232556000},"page":"4218-4227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A prospective head-to-head comparison of 68\u00a0Ga-NOTA-3P-TATE-RGD and 68\u00a0Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours"],"prefix":"10.1007","volume":"49","author":[{"given":"Yuanyuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"5852_CR1","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/jco.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063\u201372. https:\/\/doi.org\/10.1200\/jco.2007.15.4377.","journal-title":"J Clin Oncol"},{"key":"5852_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.dld.2009.07.018","volume":"42","author":"V Zamora","year":"2010","unstructured":"Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis. 2010;42:220\u20135. https:\/\/doi.org\/10.1016\/j.dld.2009.07.018.","journal-title":"Dig Liver Dis"},{"key":"5852_CR3","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1677\/erc-09-0078","volume":"17","author":"DJ Kwekkeboom","year":"2010","unstructured":"Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-73. https:\/\/doi.org\/10.1677\/erc-09-0078.","journal-title":"Endocr Relat Cancer"},{"key":"5852_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508\u201318. https:\/\/doi.org\/10.2967\/jnumed.106.035667.","journal-title":"J Nucl Med"},{"key":"5852_CR5","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00259-012-2123-y","volume":"39","author":"L Kabasakal","year":"2012","unstructured":"Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET\/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271\u20137. https:\/\/doi.org\/10.1007\/s00259-012-2123-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5852_CR6","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864\u201370. https:\/\/doi.org\/10.2967\/jnumed.111.091165.","journal-title":"J Nucl Med"},{"key":"5852_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000225951","volume":"90","author":"DJ Kwekkeboom","year":"2009","unstructured":"Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kud\u0142a B, de Herder WW, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220\u20136. https:\/\/doi.org\/10.1159\/000225951.","journal-title":"Neuroendocrinology"},{"key":"5852_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"5852_CR9","doi-asserted-by":"publisher","first-page":"16932","DOI":"10.18632\/oncotarget.24524","volume":"9","author":"RP Baum","year":"2018","unstructured":"Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with (90)yttrium and (177)lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9:16932\u201350. https:\/\/doi.org\/10.18632\/oncotarget.24524.","journal-title":"Oncotarget"},{"key":"5852_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/rlu.0000000000002680","volume":"44","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Wang H, Tan H, Cui X, Yao S, Zang J, et al. Evaluation of lung cancer and neuroendocrine neoplasm in a single scan by targeting both somatostatin receptor and integrin \u03b1v\u03b23. Clin Nucl Med. 2019;44:687\u201394. https:\/\/doi.org\/10.1097\/rlu.0000000000002680.","journal-title":"Clin Nucl Med"},{"key":"5852_CR11","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00259-007-0427-0","volume":"34","author":"Z Wu","year":"2007","unstructured":"Wu Z, Li ZB, Cai W, He L, Chin FT, Li F, et al. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2007;34:1823\u201331. https:\/\/doi.org\/10.1007\/s00259-007-0427-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5852_CR12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.7150\/thno.6989","volume":"3","author":"S Ji","year":"2013","unstructured":"Ji S, Zheng Y, Shao G, Zhou Y, Liu S. Integrin \u03b1(v)\u03b23-targeted radiotracer (99m)Tc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin \u03b1(v)\u03b23 RGD2 therapy. Theranostics. 2013;3:816\u201330. https:\/\/doi.org\/10.7150\/thno.6989.","journal-title":"Theranostics"},{"key":"5852_CR13","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2967\/jnumed.115.160648","volume":"56","author":"K Zheng","year":"2015","unstructured":"Zheng K, Liang N, Zhang J, Lang L, Zhang W, Li S, et al. 68Ga-NOTA-PRGD2 PET\/CT for integrin imaging in patients with lung cancer. J Nucl Med. 2015;56:1823\u20137. https:\/\/doi.org\/10.2967\/jnumed.115.160648.","journal-title":"J Nucl Med"},{"key":"5852_CR14","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1021\/mp5003224","volume":"11","author":"D Li","year":"2014","unstructured":"Li D, Zhao X, Zhang L, Li F, Ji N, Gao Z, et al. (68)Ga-PRGD2 PET\/CT in the evaluation of glioma: a prospective study. Mol Pharm. 2014;11:3923\u20139. https:\/\/doi.org\/10.1021\/mp5003224.","journal-title":"Mol Pharm"},{"key":"5852_CR15","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s00259-007-0692-y","volume":"35","author":"ZB Li","year":"2008","unstructured":"Li ZB, Chen K, Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging. 2008;35:1100\u20138. https:\/\/doi.org\/10.1007\/s00259-007-0692-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5852_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2967\/jnumed.117.199760","volume":"59","author":"GP Nicolas","year":"2018","unstructured":"Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, et al. Sensitivity comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59:915\u201321. https:\/\/doi.org\/10.2967\/jnumed.117.199760.","journal-title":"J Nucl Med"},{"key":"5852_CR17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2967\/jnumed.119.235093","volume":"61","author":"W Zhu","year":"2020","unstructured":"Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, et al. Head-to-head comparison of (68)Ga-DOTA-JR11 and (68)Ga-DOTATATE PET\/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. J Nucl Med. 2020;61:897\u2013903. https:\/\/doi.org\/10.2967\/jnumed.119.235093.","journal-title":"J Nucl Med"},{"key":"5852_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/rlu.0000000000003447","volume":"46","author":"EB Veenstra","year":"2021","unstructured":"Veenstra EB, de Groot DJA, Brouwers AH, Walenkamp AME, Noordzij W. Comparison of 18F-DOPA versus 68Ga-DOTATOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms. Clin Nucl Med. 2021;46:195\u2013200. https:\/\/doi.org\/10.1097\/rlu.0000000000003447.","journal-title":"Clin Nucl Med"},{"key":"5852_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/cen.14312","volume":"94","author":"E Ouvrard","year":"2021","unstructured":"Ouvrard E, Chevalier E, Addeo P, Sahakian N, Detour J, Goichot B, et al. Intraindividual comparison of (18) F-FDOPA and (68) Ga-DOTATOC PET\/CT detection rate for metastatic assessment in patients with ileal neuroendocrine tumours. Clin Endocrinol (Oxf). 2021;94:66\u201373. https:\/\/doi.org\/10.1111\/cen.14312.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"5852_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/rlu.0000000000003450","volume":"46","author":"C Ansquer","year":"2021","unstructured":"Ansquer C, Touchefeu Y, Faivre-Chauvet A, Leux C, Le Bras M, R\u00e9genet N, et al. Head-to-head comparison of 18F-DOPA PET\/CT and 68Ga-DOTANOC PET\/CT in patients with midgut neuroendocrine tumors. Clin Nucl Med. 2021;46:181\u20136. https:\/\/doi.org\/10.1097\/rlu.0000000000003450.","journal-title":"Clin Nucl Med"},{"key":"5852_CR21","doi-asserted-by":"publisher","unstructured":"Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with (68)Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2021.https:\/\/doi.org\/10.1007\/s00259-021-05512-y","DOI":"10.1007\/s00259-021-05512-y"},{"key":"5852_CR22","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","volume":"47","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, et al. [(18)F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [(68)Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47:3033\u201346. https:\/\/doi.org\/10.1007\/s00259-020-04918-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5852_CR23","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.2217\/fon.14.139","volume":"10","author":"CB Johnbeck","year":"2014","unstructured":"Johnbeck CB, Knigge U, Kj\u00e6r A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10:2259\u201377. https:\/\/doi.org\/10.2217\/fon.14.139.","journal-title":"Future Oncol"},{"key":"5852_CR24","doi-asserted-by":"publisher","first-page":"115094","DOI":"10.1016\/j.bmc.2019.115094","volume":"27","author":"B Liu","year":"2019","unstructured":"Liu B, Zhang Z, Wang H, Yao S. Preclinical evaluation of a dual sstr2 and integrin \u03b1(v)\u03b2(3)-targeted heterodimer [(68)Ga]-NOTA-3PEG(4)-TATE-RGD. Bioorg Med Chem. 2019;27:115094. https:\/\/doi.org\/10.1016\/j.bmc.2019.115094.","journal-title":"Bioorg Med Chem"},{"key":"5852_CR25","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2967\/jnumed.120.244798","volume":"62","author":"T Binderup","year":"2021","unstructured":"Binderup T, Knigge U, Johnbeck CB, Loft A, Berthelsen AK, Oturai P, et al. (18)F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study. J Nucl Med. 2021;62:808\u201315. https:\/\/doi.org\/10.2967\/jnumed.120.244798.","journal-title":"J Nucl Med"},{"key":"5852_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.7150\/thno.18068","volume":"7","author":"DL Chan","year":"2017","unstructured":"Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7:1149\u201358. https:\/\/doi.org\/10.7150\/thno.18068.","journal-title":"Theranostics"},{"key":"5852_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/rlu.0000000000003937","volume":"47","author":"AR Hayes","year":"2022","unstructured":"Hayes AR, Furtado O\u2019Mahony L, Quigley AM, Gnanasegaran G, Caplin ME, Navalkissoor S, et al. The combined interpretation of 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT in metastatic gastroenteropancreatic neuroendocrine tumors: a classification system with prognostic impact. Clin Nucl Med. 2022;47:26\u201335. https:\/\/doi.org\/10.1097\/rlu.0000000000003937.","journal-title":"Clin Nucl Med"},{"key":"5852_CR28","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00259-013-2369-z","volume":"40","author":"S Severi","year":"2013","unstructured":"Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, et al. Role of 18FDG PET\/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:881\u20138. https:\/\/doi.org\/10.1007\/s00259-013-2369-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5852_CR29","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1007\/s00259-021-05236-z","volume":"48","author":"S Nicolini","year":"2021","unstructured":"Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2021;48:3260\u20137. https:\/\/doi.org\/10.1007\/s00259-021-05236-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5852_CR30","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.2967\/jnumed.119.241414","volume":"61","author":"J Zhang","year":"2020","unstructured":"Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP. Prognostic value of (18)F-FDG PET\/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide therapy. J Nucl Med. 2020;61:1560\u20139. https:\/\/doi.org\/10.2967\/jnumed.119.241414.","journal-title":"J Nucl Med"},{"key":"5852_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2967\/jnumed.116.178095","volume":"58","author":"E Panagiotidis","year":"2017","unstructured":"Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, et al. Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET\/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med. 2017;58:91\u20136. https:\/\/doi.org\/10.2967\/jnumed.116.178095.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05852-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T17:05:06Z","timestamp":1664557506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05852-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["5852"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05852-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institute Review Board of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and this study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}